Compare Moderna, Inc. (MRNA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wells Fargo & Co — how do they compare? Moderna, Inc. trades at $60.2 (market cap $24.18B), while Wells Fargo & Co trades at $88.13 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 10.9× Moderna, Inc.'s market cap, and Wells Fargo & Co pays a 2.29% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WFC | |
|---|---|---|
Market Cap | $24.18B | $264.66B |
Sector | Health | Financials |
52-Week High | $81.80 | $96.40 |
52-Week Low | $22.36 | $73.42 |
Enterprise Value | $20.33B | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Wells Fargo (WFC) trades at $87.55, up 0.34% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 12.72, net income margin of 25.97%, and ROE of 13.13%. Recent earnings beat expectations in Q2 2026, and the company is expanding digital services like tokenized deposits. Analyst consensus is mixed but leans positive, with a price target of $97.64.
The outlook for WFC is favorable, driven by earnings growth and strategic innovations, though risks include volatile cash flows and economic sensitivity. Upside potential exists if the company meets future earnings and maintains profitability, but investors should monitor execution and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
